Renal Cell Carcinoma (RCC) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035

Renal Cell Carcinoma (RCC) Market Outlook

Thelansis's "Renal Cell Carcinoma (RCC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Renal Cell Carcinoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Renal Cell Carcinoma (RCC) Overview

Renal cell carcinoma (RCC) is the most common malignancy of the kidney, with clear cell RCC representing approximately 75% of cases - characterised by biallelic VHL tumour suppressor gene inactivation, driving constitutive HIF-mediated VEGF and mTOR pathway upregulation and angiogenic programme activation. Papillary and chromophobe subtypes constitute the principal non-clear cell histologies, each harbouring distinct molecular drivers. Tobacco smoking, obesity, hypertension, and hereditary syndromes - Von Hippel-Lindau, hereditary papillary RCC, and Birt-Hogg-Dube - represent established risk factors. Patients present with the classical triad of haematuria, flank pain, and palpable mass - increasingly incidentally detected on cross-sectional imaging - alongside paraneoplastic manifestations including hypercalcaemia, polycythaemia, and stauffer syndrome. Diagnosis integrates CT or MRI characterisation, with biopsy reserved for diagnostically uncertain or metastatic cases alongside molecular profiling. Surgical resection - radical or nephron-sparing nephrectomy - remains curative for localised disease. Metastatic RCC management has been transformed by combination immunotherapy - nivolumab-ipilimumab for intermediate and poor-risk disease - and VEGFR tyrosine kinase inhibitor combinations with checkpoint inhibitors - pembrolizumab-axitinib, nivolumab-cabozantinib, and lenvatinib-pembrolizumab - as first-line standards. Belzutifan, a HIF-2a inhibitor, represents a paradigm-shifting targeted advance in VHL-driven and refractory RCC. Prognosis varies with stage and risk stratification; multidisciplinary management, surveillance imaging, and patient-centred supportive care are integral to optimising long-term outcomes.

Key Highlights

• In France, survival-adjusted prevalent RCC cases are projected to increase from 610,586 in 2025 to 654,698 by 2035.
• RCC remains a major kidney malignancy with growing reliance on biomarker-driven treatment approaches.
• Combination immunotherapies and VEGF-targeted therapies continue to transform patient outcomes.
• Significant unmet need persists in resistant and metastatic RCC cases.

Market Overview

• The Italy RCC market is projected to grow from USD 210 million in 2025 to USD 490 million by 2035.
• Growth is supported by increasing adoption of immune checkpoint inhibitors and targeted therapies.
• Pipeline innovation in combination regimens is expected to create additional commercial opportunities.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Zhejiang Haichang Biotech Co., Ltd.
• Bristol-Myers Squibb
• Merck Sharp & Dohme LLC
• Oncorena AB
• Novartis Pharmaceuticals
• HiberCell, Inc.
• Hoffmann-La Roche
• Xynomic Pharmaceuticals, Inc.
• Exelixis
• Eisai Inc.
• AVEO Pharmaceuticals, Inc.
• Imbioray (Hangzhou) Biomedicine Co., Ltd.
• Incyte Corporation
• Daiichi Sankyo
• Akeso
• BeiGene
• Shanghai Henlius Biotech
• Compass Therapeutics
• AstraZeneca
• HiFiBiO Therapeutics
• Janux Therapeutics